Is compounded semaglutide safe? How do I avoid sketchy providers?

Short answer

• Compounded semaglutide is riskier than using FDA‑approved semaglutide products (Wegovy, Ozempic, Rybelsus) because compounded product is not reviewed by the FDA for safety, potency, sterility, or consistent dosing. If you can, get the FDA‑approved pen/tablet from a licensed prescriber and specialty pharmacy. If compounding is necessary (cost or supply issues), choose the compounding source carefully.

Why compounded semaglutide can be unsafe

• Potency and purity may vary — dose can be too strong or too weak.
• Sterility risks — injections from poorly controlled sterile compounding can cause infections or sepsis.
• Lack of regulatory review — compounded lots don’t have the same quality testing or labeling as manufacturer products.
• No clinical data for compounded formulations (stability, excipients, delivery devices).
• Increased risk from sketchy supply chains or mislabeled/counterfeit drug.

When compounding might be reasonable

• A true medical need that an approved product can’t meet (patient‑specific dose or excipient allergy). Even then it should be done by a high‑quality compounding pharmacy under close medical supervision.

How to avoid sketchy providers — practical checklist

• Require a legitimate prescription and a proper medical evaluation:
  • The prescriber should be a licensed clinician who documents medical history, baseline labs, and follow‑up plan.
• Use licensed pharmacies only:
  • Prefer major chain or established specialty pharmacies that dispense FDA‑approved pens (CVS Specialty, Accredo/Express Scripts, Optum/OptumRx Specialty, Walgreens Specialty, Diplomat/Optum). These will supply manufacturer product when available.
• If you must use a compounded product, prefer higher‑regulated sources:
  • Use an FDA‑registered 503B outsourcing facility (they follow current good manufacturing practices and are subject to FDA inspection) or a state‑licensed 503A compounding pharmacy that is accredited and follows USP sterile compounding standards (USP <797>).
  • Look for accreditation from organizations such as ACHC (Accreditation Commission for Health Care) or evidence they follow USP <797> sterile compounding standards.
• Ask direct questions:
  • “Are you using FDA‑approved semaglutide pens/tablets or a compounded vial?”
  • “If compounded: what is your source, can you provide a certificate of analysis (COA) and lot number, and do you follow USP <797>?”
  • “Are you a 503B outsourcing facility or ACHC‑accredited?”
  • “How is the product stored and shipped? Who will do injection training and follow‑up?”
• Watch for red flags:
  • Unusually low prices, no prescription required, cash‑only clinics that won’t provide source details, providers that ship from overseas with no tracking/lot info, providers that won’t arrange follow‑up labs or monitoring.
• Verify credentials:
  • Check the prescriber with your state medical board and the pharmacy with your state board of pharmacy. If it’s a 503B, see if it’s on the FDA’s outsourcing facility list.

What to do if you suspect a problem

• Don’t use product that looks tampered with, is unlabeled, or came without lot information.
• Report adverse events or suspect counterfeit/contaminated products to FDA MedWatch and your state board of pharmacy/medical board.

Safer alternatives to compounded semaglutide

• Ask your clinician about FDA‑approved semaglutide options: Wegovy (for weight loss) or Ozempic/Rybelsus (for diabetes; some are used off‑label for weight). These come with manufacturer quality, established dosing pens/tablets, and safety data.
• Use insured specialty pharmacies that work with manufacturers to get access and financial assistance programs if cost is the issue.

If you want, I can:

• Help you draft the questions to ask a clinic or pharmacy.
• Look up whether a specific pharmacy or telemedicine service is 503B/ACHC‑accredited (tell me the name).